Amgen’s second quarter results outpaced Wall Street’s expectations, with management emphasizing strong demand for its ...

Clinical trial tech outfit Medidata has elevated a new strategy leader from within. | Clinical trial tech outfit Medidata has elevated a new strategy leader from within. Industry veteran Lisa ...

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Amgen AMGN delivered yet another strong quarterly performance. Its second-quarter 2025 earnings and sales beat estimates. The ...

Amgen (NASDAQ:AMGN) is set to release its earnings on Tuesday, August 5, 2025. Historically, Amgen's stock has shown a ...

Amgen is also a component of the Dow Jones Industrial Average and Nasdaq-100 index, making its shares highly liquid. Lastly, the biotech's annualized yield now sits at an all-time high.

Dec 12 (Reuters) - Amgen Inc (AMGN.O) on Monday agreed to buy Horizon Therapeutics Plc (HZNP.O) in a deal valued at $27.8 billion, fortifying its rare diseases portfolio in the biggest buyout in ...

Amgen’s shares fell 21 cents to $89.29 in trading Tuesday. The company’s case adds to a string of major settlements the federal government has secured from pharmaceutical giants.